These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Ozempic, Wegovy, Saxenda, Trulicity: These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for fo ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.

Analyses were conducted separately for patients with and without type 2 diabetes. The study found that most adults with overweight or obesity discontinued GLP-1 RA therapy within a year, with ...

After just a few years on the market, a new wave of GLP-1 drugs approved for weight loss have upended what we know about obesity. By now, these are household names: Mounjaro. Wegovy. Zepbound ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

BUFFALO, N.Y. — A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a direct causal link with the drugs has not been established.

The absolute risk for thyroid cancer is low among patients receiving GLP-1 RA therapy, but risk is elevated in the first year of treatment.

The data, from electronic health records of more than 125,000 adults who initiated GLP-1 RA treatment in the United States, showed that just over half stopped using GLP-1 RAs at 1 year.

Researchers found that GLP-1 RA use was not associated with an increased risk for thyroid cancer compared with use of DPP-4i. HealthDay News — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use ...

Adam Gilden, MD, MSCE, is an associate director of the Obesity Medicine Fellowship at University of Colorado School of Medicine and associate director of the Colorado University Medicine Weight ...